Cytology
Introgen Therapeutics Reports Encouraging Phase I Trial Data for INGN 241 in Patients with Solid Tumors
Introgen Therapeutics, Inc. has published data from a phase I trial of INGN 241, a novel cancer therapy, in patients with solid tumors. The trial demonstrated that direct injection of INGN 241 induced programmed cell death in 100% of the tumors treated, even in patients who had failed prior therapy